143 related articles for article (PubMed ID: 15687926)
21. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
[TBL] [Abstract][Full Text] [Related]
22. [The ocular hypotensive effect and safety of 0.2% brimonidine].
Yu M; Li Y; Ge J
Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
[TBL] [Abstract][Full Text] [Related]
23. The adverse effect of perioperative brimonidine tartrate 0.2% on flap adherence and enhancement rates in laser in situ keratomileusis patients.
Walter KA; Gilbert DD
Ophthalmology; 2001 Aug; 108(8):1434-8. PubMed ID: 11470696
[TBL] [Abstract][Full Text] [Related]
24. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
Melamed S; David R
Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394
[TBL] [Abstract][Full Text] [Related]
25. Allergic reactions to brimonidine in patients treated for glaucoma.
Blondeau P; Rousseau JA
Can J Ophthalmol; 2002 Feb; 37(1):21-6. PubMed ID: 11865954
[TBL] [Abstract][Full Text] [Related]
26. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma.
Korsch E; Grote A; Seybold M; Soditt V
Eur J Pediatr; 1999 Aug; 158(8):685. PubMed ID: 10445353
[No Abstract] [Full Text] [Related]
27. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
[TBL] [Abstract][Full Text] [Related]
28. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
Adkins JC; Balfour JA
Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
Schadlu R; Maus TL; Nau CB; Brubaker RF
Arch Ophthalmol; 1998 Nov; 116(11):1441-4. PubMed ID: 9823343
[TBL] [Abstract][Full Text] [Related]
30. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty.
David R; Spaeth GL; Clevenger CE; Perell HF; Siegel LI; Henry JC; Stiles MC; Passo MS; Stamper RL; Walt JG
Arch Ophthalmol; 1993 Oct; 111(10):1387-90. PubMed ID: 8105773
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
Schuman JS
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
Serle JB
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
[TBL] [Abstract][Full Text] [Related]
33. Acute and chronic effects of brimonidine 0.2% on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: an open-label, uncontrolled, prospective study.
Vetrugno M; Maino A; Cantatore F; Ruggeri G; Cardia L
Clin Ther; 2001 Sep; 23(9):1519-28. PubMed ID: 11589264
[TBL] [Abstract][Full Text] [Related]
34. Charles Bonnet syndrome precipitated by brimonidine tartrate eye drops.
Tomsak RL; Zaret CR; Weidenthal D
Br J Ophthalmol; 2003 Jul; 87(7):917. PubMed ID: 12812898
[No Abstract] [Full Text] [Related]
35. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
[TBL] [Abstract][Full Text] [Related]
36. Systemic side effects of ophthalmic drops.
Levy Y; Zadok D
Clin Pediatr (Phila); 2004; 43(1):99-101. PubMed ID: 14968900
[TBL] [Abstract][Full Text] [Related]
37. Brimonidine (Alphagan): a clinical profile four years after launch.
David R
Eur J Ophthalmol; 2001; 11 Suppl 2():S72-7. PubMed ID: 11592536
[TBL] [Abstract][Full Text] [Related]
38. The teardrop sign: a rare dermatological reaction to brimonidine.
Scruggs JT; Whiteside-Michel J; Brodsky MC
Br J Ophthalmol; 2000 Jun; 84(6):671-2. PubMed ID: 10896417
[No Abstract] [Full Text] [Related]
39. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
Stewart WC; Sharpe ED; Harbin TS; Pastor SA; Day DG; Holmes KT; Stewart JA
Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
[TBL] [Abstract][Full Text] [Related]
40. Is brimonidine ophthalmic a safe therapy for infants?
Daubert GP
J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
